Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02706626
What this trial is testing

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Who this might be right for
Non-Small Cell Lung Cancer
Criterium, Inc. 32
Testing effectiveness (Phase 2)UnknownNCT04074993
What this trial is testing

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Who this might be right for
Non Small Cell Lung Cancer
JI-YOUN HAN 35
Post-approval studies (Phase 4)Not Yet RecruitingNCT06785584
What this trial is testing

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Who this might be right for
ALK-positive Advanced NSCLCALK-positive Non-small Cell Lung Cancer (NSCLC)MPR+1 more
Fujian Medical University Union Hospital 30
Not applicableActive Not RecruitingNCT05721950
What this trial is testing

Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 154
Not applicableEnded earlyNCT02554591
What this trial is testing

Genomic Landscape of Ceritinib

Who this might be right for
Carcinoma, Non-Small-Cell LungNon-small Lung CancerNon-Small Cell Lung Cancer
Washington University School of Medicine 6
Not applicableStudy completedNCT03718117
What this trial is testing

Descriptive Observational Study ALK-2016-CPHG

Who this might be right for
NSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement
Pfizer 73
Testing effectiveness (Phase 2)Study completedNCT02094573
What this trial is testing

Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 222
Testing effectiveness (Phase 2)UnknownNCT05351320
What this trial is testing

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jinming Yu 40
Testing effectiveness (Phase 2)Looking for participantsNCT07491497
What this trial is testing

TRI-611 in ALK-Positive NSCLC

Who this might be right for
ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc. 160
Not applicableUnknownNCT06410040
What this trial is testing

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Who this might be right for
ALK-positive Non-small Cell Lung CancerBrain MetastasesMeningeal Metastasis
Sichuan Cancer Hospital and Research Institute 28
Post-approval studies (Phase 4)Ended earlyNCT03672643
What this trial is testing

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Who this might be right for
ALK or ROS1-positive NSCLC
Pfizer 41
Testing effectiveness (Phase 2)Study completedNCT03049618
What this trial is testing

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Who this might be right for
ALK Gene MutationBRAF Gene MutationEGFR Gene Mutation+9 more
University of Southern California 42
Not applicableActive Not RecruitingNCT07556549
What this trial is testing

Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Who this might be right for
Non-Small Cell Lung Cancer ALK-positive
Pfizer 50
Not applicableNot Yet RecruitingNCT06690541
What this trial is testing

Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

Who this might be right for
Lung Cancer, Non-Small Cell
Peking University Cancer Hospital & Institute 100
Testing effectiveness (Phase 2)WithdrawnNCT05948462
What this trial is testing

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
SCRI Development Innovations, LLC
Large-scale testing (Phase 3)Looking for participantsNCT06868277
What this trial is testing

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small Cell Lung
AstraZeneca 830
Testing effectiveness (Phase 2)UnknownNCT02927340
What this trial is testing

Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital 30
Early research (Phase 1)Ended earlyNCT01441128
What this trial is testing

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small Cell LungAdenocarcinomaCarcinoma, Squamous Cell+1 more
National Cancer Institute (NCI) 20
Not applicableNo Longer AvailableNCT05100134
What this trial is testing

Managed Access Programs for LDK378, Ceritinib

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Not applicableActive Not RecruitingNCT06269133
What this trial is testing

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

Who this might be right for
Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 1,000
Next Page